A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy-Reference-Cited by-同舟云学术

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy

Published:2016-10 Issue:10 Volume:38 Page:2159-2170
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Kim Kwang-il,Shin Mi-Seung,Ihm Sang-Hyun,Youn Ho-Joong,Sung Ki-Chul,Chae Shung Chull,Nam Chang-Wook,Seo Hong Seog,Park Seong-Mi,Rhee Moo-Yong,Kim Moo Hyun,Cha Kwang Soo,Kim Yong-Jin,Kim Jae-Joong,Chun Kook Jin,Yoo Byung-Su,Park Sungha,Shin Eun-Seok,Kim Dong-Soo,Il Kim Doo,Kim Kye Hun,Joo Seung-Jae,Jeong Jin-Ok,Shin Jinho,Kim Cheol Ho

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference30 articles.

1. Shattuck Lecture. The hypertension paradox—more uncontrolled disease despite improved therapy;Chobanian;N Engl J Med,2009

2. Hypertension;Poulter;Lancet,2015

3. Current status and characteristics of hypertension treatment by primary physicians in Korea: data from Korean epidemiology study on hypertension (KEY study);Kim;Am J Hypertens,2008

4. Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals;Okonofua;Hypertension,2006

5. Initial monotherapy and combination therapy and hypertension control the first year;Egan;Hypertension,2012

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy;Clinical Hypertension;2022-12-01

2. Newer Angiotensin Receptor Blockers;Hypertension and Cardiovascular Disease in Asia;2022

3. Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives;Current Pharmaceutical Design;2021-03-03

4. Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects;Translational and Clinical Pharmacology;2021

5. Fimasartan: A new armament to fight hypertension;Journal of Family Medicine and Primary Care;2019